文献速递角膜与眼表疾病

重组人神经生长因子滴眼液治疗干眼症患者的效果:一项IIa期、开放标签、多剂量研究

Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study.
PubMed 文献 · Br J Ophthalmol · 2019-04-03

这项IIa期前瞻性开放标签多剂量临床试验纳入40例中重度干眼症患者,分别接受20 µg/mL(G1)或4 µg/mL(G2)重组人神经生长因子滴眼液双眼每日两次治疗28天。两种浓度均安全耐受,两组干眼症状频率与严重程度及眼表损伤均显著改善,但泪液功能仅G1改善。

要点

  • 两种浓度rhNGF滴眼液均安全且耐受良好,G1有14例、G2有15例发生至少1次不良事件。
  • 两组干眼症状频率与严重程度及眼表损伤均显著改善。
  • 泪液功能仅在20 µg/mL组(G1)改善。

核心结论

  • 本研究表明两种剂量的rhNGF滴眼液均安全且有效改善干眼症的症状和体征。
  • 随机临床试验正在进行以确认rhNGF在干眼症中的治疗获益。

研究设计与样本

  • IIa期、前瞻性、开放标签、多剂量临床试验(NCT02101281),连续纳入40例中重度干眼症患者。
  • 患者接受rhNGF滴眼液20 µg/mL(G1)或4 µg/mL(G2),双眼每日两次,共28天。
  • 主要结局指标为治疗中出现的不良事件、干眼症状评估量表(SANDE)、眼表染色和Schirmer试验。

主要发现

  • 40例纳入患者中39例完成试验。
  • 29例患者发生至少1次不良事件(G1 14例,G2 15例),其中11例有至少1次相关不良事件(G1 8例,G2 3例)。
  • 两组干眼症状频率与严重程度及眼表损伤均显著改善。
  • 泪液功能仅在G1改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dry eye disease (DED) affects more than 14% of the elderly population causing decrease of quality of life, high costs and vision impairment. Current treatments for DED aim at lubricating and controlling inflammation of the ocular surface. Development of novel therapies targeting different pathogenic mechanisms is sought-after. The aim of this study is to evaluate safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops in patients with DED. METHODS: Forty consecutive patients with moderate to severe DED were included in a phase IIa, prospective, open label, multiple-dose, clinical trial to receive rhNGF eye drops at 20 µg/mL (Group 1: G1) or at 4 µg/mL (Group 2: G2) concentrations, two times a day in both eyes for 28 days (NCT02101281). The primary outcomes measures were treatment-emerged adverse events (AE), Symptoms Assessment in Dry Eye (SANDE) scale, ocular surface staining and Schirmer test. RESULTS: Of 40 included patients, 39 completed the trial. Both tested rhNGF eye drop concentrations were safe and well tolerated. Twenty-nine patients experienced at least one AE (14 in G1 and 15 in G2), of which 11 had at least 1 related AE (8 in G1 and 3 in G2). Both frequency and severity of DED symptoms and ocular surface damage showed significant improvement in both groups, while tear function improved only in G1. CONCLUSIONS: The data of this study indicate that rhNGF eye drops in both doses is safe and effective in improving symptoms and signs of DED. Randomised clinical trials are ongoing to confirm the therapeutic benefit of rhNGF in DED. TRIAL REGISTRATION NUMBER: NCT02101281.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sacchetti M, Lambiase A, Schmidl D, et al. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. Br J Ophthalmol. 2019. PMID: 30944103. doi:10.1136/bjophthalmol-2018-312470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。